Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 21;10(19):e37928.
doi: 10.1016/j.heliyon.2024.e37928. eCollection 2024 Oct 15.

SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43

Affiliations

SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43

Micaela Garziano et al. Heliyon. .

Abstract

Background: The recent SARS-CoV-2 pandemic renewed interest toward other non-severe acute respiratory syndrome human coronaviruses. Among these, OC43 is a seasonal human coronavirus widely diffused in the population (90 % seroprevalence in adults) which is responsible for mild respiratory symptoms. As OC43 protective immunity is short lasting, we investigated whether humoral immunity to SARS-CoV-2, induced by vaccination or spontaneous infection, protects against OC43 re-infection at either systemic or mucosal level.

Methods: A neutralization assay was conducted against "wild type" SARS-CoV-2 lineage B.1 (EU) and OC43 in VeroE6 cell lines using plasma and saliva samples from 49 subjects who were never infected and received three BNT162b2 RNA vaccine doses (SARS-CoV-2-vaccinated: SV) and from 25 SARS-CoV-2-infected and vaccinated subjects (SIV). The assays were performed right before (T0), fifteen days (T1) and three months (T2) after the third dose administration (SV) or post-infection (SIV).

Results: After the third vaccination dose was administered, SARS-CoV-2-specific neutralizing activity (NA) significantly augmented in SV saliva (p < 0.05) and plasma (p < 0.0001); yet, this NA was not protective against OC43. Conversely, in SIV, at T1, natural infection significantly increased NA against both SARS-CoV-2 (p < 0.01) and OC43 (p < 0.05) at systemic as well as mucosal level; still, this cross-reactivity vanished at T2. Of note, NA against SARS-CoV-2 and OC43 was shown to be higher in SIV compared to SV in plasma and saliva, as well; though, statistically significant differences were evident only in the oral mucosa at T1 (p < 0.05).

Conclusions: Our findings show that SARS-CoV-2 spontaneous infection triggers a more comprehensive and cross-reactive immunity than vaccine-induced immunity, protecting against OC43 at the systemic and mucosal levels. These results support the development of a pan-coronavirus vaccine able to prompt cross-reactive immunity even against seasonal coronaviruses, which could have enormous economic and health benefits globally.

Keywords: Cross-reactive immunity; Human coronaviruses; Mucosal immunity; OC43; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Plasma and saliva neutralizing activity (NA) in SARS-CoV-2-vaccinated subjects (SV). NA against SARS-CoV-2 and OC43 in plasma samples of SV group are reported in panel A and B respectively, while NA against SARS-CoV-2 in saliva samples are shown in panel C and OC43 in panel D. 49 plasma samples and 15 saliva samples of SV were tested against SARS-CoV-2 and OC43. Mean values ± standard errors are reported. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,∗∗∗∗p < 0.0001 To compare three time points in SV NA response one way ANOVA Kruskall-Wallis test was performed.
Fig. 2
Fig. 2
Plasma and saliva neutralizing activity (NA) in SARS-CoV-2-infected subjects (SIV). NA against SARS-CoV-2 and OC43 in plasma samples of SIV group are reported in panel A and B respectively, while NA against SARS-CoV-2 in saliva samples are shown in panel C and OC43 in panel D. 24 plasma have been tested against SARS-CoV-2 and 19 against OC43. 25 saliva samples were tested against SARS-CoV-2 and 18 aganist OC43. Mean values ± standard errors are reported. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,∗∗∗∗p < 0.0001 To compare three time points in SIV NA response one way ANOVA Kruskall-Wallis test was performed.
Fig. 3
Fig. 3
Neutralizing activity (NA) in plasma specimens from SARS-CoV-2-infected (SIV) and vaccinated (SV) individuals. Comparison of neutralizing activity (NA) in plasma against SARS-CoV-2 (A) and OC43 (B) from SIV and SV at T0, T1, and T2. Mean values ± standard errors are reported. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,∗∗∗∗p < 0.0001. To compare SV and SIV groups unpaired T-test was used.
Fig. 4
Fig. 4
Comparison of neutralizing activity (NA) in SARS-CoV-2-vaccinated (SV) and SARS-CoV-2-infected (SIV) saliva specimens. Panel A shows comparison between SV and SIV in saliva specimens against SARS-CoV-2, and panel B shows the results against OC43. Triangles identify NA to SARS-CoV-2 while circles identify NA to OC43. Mean values ± standard errors are reported. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,∗∗∗∗p < 0.0001. To compare SV and SIV groups unpaired T-test was used.

Similar articles

Cited by

References

    1. Cicaloni V., Costanti F., Pasqui A., Bianchini M., Niccolai N., Bongini P. A bioinformatics approach to investigate structural and non-structural proteins in human coronaviruses. Front. Genet. 2022;13 doi: 10.3389/fgene.2022.891418. - DOI - PMC - PubMed
    1. Kapikian A.Z. The coronaviruses. Dev. Biol. Stand. 1975;28:42–64. - PubMed
    1. Cappelletti G., Colombrita C., Limanaqi F., Invernizzi S., Garziano M., Vanetti C., Moscheni C., Santangelo S., Zecchini S., Trabattoni D., et al. Human motor neurons derived from induced pluripotent stem cells are susceptible to SARS-CoV-2 infection. Front. Cell. Neurosci. 2023;17 doi: 10.3389/fncel.2023.1285836. - DOI - PMC - PubMed
    1. Koralnik I.J., Tyler K.L. Covid ‐19: a global threat to the nervous system. Ann. Neurol. 2020;88:1–11. doi: 10.1002/ana.25807. - DOI - PMC - PubMed
    1. Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China. JAMA Neurol. 2020;77:683. doi: 10.1001/jamaneurol.2020.1127. - DOI - PMC - PubMed

LinkOut - more resources